1 empagliflozin, via switching metabolism towards lipid ... · 39 these data suggest that...
TRANSCRIPT
1
Empagliflozin, via Switching Metabolism towards Lipid Utilization, Moderately 1
Increases LDL-cholesterol Levels through Reduced LDL Catabolism. 2
3
Running head: F. Briand et al. SGLT2 inhibition and LDL-C 4
François Briand1,#,*
Eric Mayoux2,#
, Emmanuel Brousseau1, Noémie Burr
1, Isabelle Urbain
1, 5
Clément Costard1, Michael Mark
2, Thierry Sulpice
1. 6
1Physiogenex SAS, Prologue Biotech, 516 Rue Pierre et Marie Curie, 31670 Labège, France. 7
2Boehringer Ingelheim Pharma, CardioMetabolic Diseases Research, BirkendorferStraße 65, 8
88397 Biberach an der Riss, Germany. 9
#Both authors contributed equally to this work. 10
This work has been funded by Boehringer Ingelheim Pharma. 11
*Corresponding author : François Briand, Ph.D, Physiogenex SAS, Prologue Biotech, 516 12
Rue Pierre et Marie Curie, 31670 Labège, France. 13
Tel.: +33 561 287 048 14
Fax: +33 561 287 043 15
E-mail: [email protected] 16
-17 pages, 1 table, 3 figures, 19 references 17
-abstract word count: 215 18
-manuscript total words count (excluding abstract, references and figure legends): 1999. 19
20
Page 1 of 20 Diabetes
Diabetes Publish Ahead of Print, published online April 5, 2016
2
Abstract 21
In clinical trials, small increase in LDL cholesterol has been reported with sodium-glucose co-22
transporter type 2 (SGLT2) inhibitors. The mechanisms by which the SGLT2 inhibitor 23
empagliflozin increases LDL-cholesterol levels were investigated in diet-induced 24
dyslipidemic hamsters. 25
Compared with vehicle, empagliflozin 30mg/kg/day for 2 weeks significantly reduced fasting 26
blood glucose by 18%, with significant increase in fasting plasma LDL-cholesterol, free fatty 27
acids and total ketone bodies by 25, 49 and 116%, respectively. In fasting conditions, 28
glycogen hepatic levels were further reduced by 84% with empagliflozin, while HMG-CoA 29
reductase activity and total cholesterol hepatic levels were 31 and 10% higher, respectively 30
(both P<0.05 vs. vehicle). A significant 20% reduction in hepatic LDL-receptor protein 31
expression was also observed with empagliflozin. Importantly, none of these parameters were 32
changed by empagliflozin in fed conditions. Empagliflozin significantly reduced the 33
catabolism of 3H-cholesteryl oleate labelled LDL injected intravenously by 20%, indicating 34
that empagliflozin raises LDL levels through reduced catabolism. Unexpectedly, 35
empagliflozin also reduced intestinal cholesterol absorption in vivo, which led to a significant 36
increase in LDL- and macrophage-derived cholesterol fecal excretion (both P<0.05 vs. 37
vehicle). 38
These data suggest that empagliflozin, by switching energy metabolism from carbohydrate to 39
lipid utilization, moderately increases ketones production and LDL-cholesterol levels. 40
Interestingly, empagliflozin also reduces intestinal cholesterol absorption, which in turn 41
promotes LDL- and macrophage-derived cholesterol fecal excretion. 42
Key words- SGLT2 inhibition • empagliflozin • LDL • cholesterol metabolism • reverse 43
cholesterol transport 44
Page 2 of 20Diabetes
3
Introduction 45
Specific sodium glucose co-transporter inhibitors represent an emerging and promising new 46
class of glucose lowering drugs in the management of type 2 diabetes mellitus. The unique 47
mode of action of this class of novel agents can effectively decrease blood glucose levels, 48
independently of the insulin pathway, via increasing glucose excretion in urine, i.e. glucosuria 49
(1, 2). Beside improved glycemic parameters, SGLT2 inhibitors have shown additional 50
benefits such as body weight loss and blood pressure lowering, with low risk of 51
hypoglycaemia (3). However, an increase in LDL-cholesterol (LDL-C) plasma levels has 52
been also observed in patients treated with SGLT2 inhibitors (1). The mechanism by which 53
SGLT2 inhibition raises LDL-C levels remains unclear. It has been suggested that the 54
increase in LDL-C, may be partly due to haemoconcentration, as SGLT2 inhibitors induce 55
volume contraction subsequent to increased urinary volume (4, 5). However, the transient 56
diuretic effect of SGLT2 inhibitors may not completely contribute to the observed LDL-C 57
increase. We therefore investigated the effects of the SGLT2 inhibitor empagliflozin in the 58
diet-induced insulin resistant dyslipidemic Golden Syrian hamster, a validated preclinical 59
model with similar cholesterol metabolism as compared with humans (6, 7). 60
61
62
63
64
65
66
Page 3 of 20 Diabetes
4
Methods 67
All animal protocols were approved by the local (Comité régional d’éthique de Midi-68
Pyrénées) and national (Ministère de l’Enseignement Supérieur et de la Recherche) ethical 69
committees. Male Golden Syrian hamsters (91-100g, 6 week-old, Elevage Janvier, Le Genest 70
Saint Isle, France) were fed ad libitum over 4 weeks with a high fat/high cholesterol diet 71
(HFHC, 0.5% cholesterol, 0.25% deoxycholate, 11.5% coconut oil, 11.5% corn oil) with 10% 72
fructose in the drinking water, as described (7). After 2 weeks of diet to induce dyslipidemia, 73
hamsters were randomized into 2 sets of non-radioactive (set 1) or radioactive (set 2) 74
experiments, according to their blood glucose and LDL-cholesterol levels in fed or overnight 75
fasting conditions (fasting starts at 5:00pm, blood collection at ~08:00am), and were then 76
treated orally for 2 weeks with vehicle or empagliflozin 30mg/kg once daily. The dose was 77
selected from a pilot study where glucose urine excretion was measured in this hamster model 78
treated acutely with empagliflozin 3, 10 and 30mg/kg. The 30mg/kg dose was found to 79
increase glucose urine excretion by 1200-fold vs. vehicle, while the 3 and 10mg/kg doses 80
showed slighter effect (80- and 200-fold respectively). At the end of the treatment period, a 81
first set of hamsters was used to measure biochemical parameters using commercial kits in fed 82
or overnight fasting conditions. Lipoprotein total cholesterol profile from was assessed using 83
Fast Protein Liquid Chromatography (FPLC) analysis using one pooled plasma sample (one 84
pool per treatment group), western blot analysis for LDL-receptor protein expression and 85
fecal cholesterol mass excretion were performed as described previously (7). A second set of 86
hamsters underwent radio-tracer based in vivo experiments to measure intestinal cholesterol 87
absorption, LDL-cholesteryl esters kinetics or macrophage-to-feces reverse cholesterol 88
transport, as described previously (6, 7). Intestinal cholesterol absorption was assessed after 89
administration of 14
C-cholesterol labeled olive oil by oral gavage and intraperitoneal injection 90
of poloxamer-407 (a lipase inhibitor) to measure 14
C-tracer plasma tracer appearance at time, 91
Page 4 of 20Diabetes
5
3, 5 and 6 hour after oral gavage (6). Kinetics of LDL-cholesteryl oleate were performed by 92
injecting intravenously 3H-cholesteryl oleate labeled LDL in overnight fasted hamsters, 93
previously isolated from hamsters fed the same high fat/high cholesterol diet (7). Hamsters 94
were kept fasted for the first 6 hours of the kinetic experiment and were then kept in 95
individual cages with access to food and water for feces collection over 72 hours. Plasma 3H-96
tracer decay curve was monitored over 72 hours after injection to calculate 3H-cholesteryl 97
oleate LDL fractional catabolic rate (FCR) using the SAAMII software. Liver (collected after 98
72 hours) and feces were used to measure 3H-tracer recovery in cholesterol and bile acids 99
fraction after chemical extraction (6, 7). 100
Macrophage-to-feces reverse cholesterol transport was measured over 72 hours after injecting 101
intraperitoneally 3H-cholesterol labeled / oxidized-LDL loaded J774 macrophages (6, 7). In 102
this experiment, hamsters were not fasted and had constant access to food and water over 72 103
hours. Plasma 3H-tracer appearance was measured every 24 hours and liver (collected after 72 104
hours) and feces (collected over 72 hours) were used to measure 3H-tracer recovery in 105
cholesterol and bile acids fraction after chemical extraction. 106
Data are expressed as mean ± SEM. Unpaired Student t-test or 1-way ANOVA + Dunnett 107
post-test was used for statistical analysis. A p<0.05 was considered significant. 108
109
110
111
112
113
Page 5 of 20 Diabetes
6
114
Results 115
Empagliflozin treatment significantly triggered more biochemical parameter changes in 116
overnight fasting condition than in fed condition (table 1). 117
Plasma LDL-cholesterol levels were found higher by 25% in hamsters treated with 118
empagliflozin (P<0.05 vs. vehicle) only in fasting condition. Concomitantly, fasting blood 119
glucose was reduced by 18% (P<0.05 vs. vehicle) while plasma total ketone bodies and free 120
fatty acids were raised by 116% (P<0.001 vs. vehicle) and 49% (P<0.01 vs. vehicle), 121
respectively. Hepatic total cholesterol and fatty acids levels in overnight fasting conditions 122
were 10% and 8% higher in hamsters treated with empagliflozin (both P<0.05 vs. vehicle). As 123
well, hepatic total ketone bodies levels were 14% higher with empagliflozin, although not 124
significantly. Hepatic pyruvate levels and HMG-CoA reductase activity were 19% and 31% 125
higher, respectively, in overnight fasted hamsters treated with empagliflozin (both P<0.05 vs. 126
vehicle). Compared with vehicle, hepatic glycogen levels were dramatically blunted by 84% 127
with empagliflozin (P<0.001 vs. vehicle). In sharp contrast with the fasting condition, 128
empagliflozin showed limited effects on biochemical parameters measured in fed condition 129
with the exception of minor difference on haematocrit, liver weight and plasma free glycerol 130
compared with vehicle. 131
To further confirm the raise in plasma LDL-cholesterol levels total cholesterol lipoprotein 132
profile in overnight fasted hamsters was measured by FPLC (figure 1A). As expected, 133
empagliflozin led to higher total cholesterol levels in fractions corresponding to LDL. Since 134
higher plasma LDL-cholesterol may be linked to lower LDL-receptor expression, western blot 135
analysis was also performed using liver samples collected from overnight fasted hamsters. 136
Compared with vehicle, hepatic protein expression of the LDL-receptor was found to be 137
Page 6 of 20Diabetes
7
reduced by 20% (figure 1B) in overnight fasted hamsters treated with empagliflozin (P<0.05 138
vs. vehicle). 139
As higher LDL-cholesterol levels could also be related to increased intestinal cholesterol 140
absorption, this mechanism was also measured in vivo after oral administration of 14
C-141
cholesterol labelled olive oil. Strikingly, hamsters treated with empagliflozin showed a 14
C-142
tracer plasma appearance reduced by up to 40% over 6 hours after 14
C-tracer administration, 143
indicating lower intestinal cholesterol absorption (figure 1C). In agreement with the lower 144
intestinal cholesterol absorption, fecal cholesterol mass excretion was 49% higher in hamsters 145
treated with empagliflozin (figure 1D), as compared with vehicle (P<0.01). 146
We next investigated LDL-cholesterol metabolism in vivo by injecting 3H-cholesteryl oleate 147
labelled LDL intravenously in hamsters. Empagliflozin treatment resulted in slowed 3H-tracer 148
decay curve over 72 hours, leading to a 20% reduction in LDL-cholesteryl ester catabolism 149
(figure 2A), as compared with vehicle (P<0.05). At 72 hours after 3H-cholesteryl oleate 150
labelled LDL, hepatic 3H-tracer recoveries in the whole liver and the hepatic cholesterol 151
fraction were respectively reduced by 11% (P<0.01 vs. vehicle) and 19% (P<0.001 vs. 152
vehicle) with empagliflozin treatment (figure 2B). As a result of reduced cholesterol 153
absorption in the intestine, LDL-derived 3H-cholesterol fecal excretion was 26% higher 154
(P<0.05 vs. vehicle) in hamsters treated with empagliflozin (figure 2C). 155
To investigate macrophage-to-feces reverse cholesterol transport in vivo, hamsters were 156
injected intraperitoneally with 3H-cholesterol labelled/oxidized LDL loaded macrophages. 157
Compared with vehicle, empagliflozin did not change plasma 3H-tracer appearance over 72 158
hours (figure 2D). Hepatic 3H-tracer recoveries in the whole liver and the hepatic cholesterol 159
fraction tended to be reduced with empagliflozin, although this was not significant (figure 160
2E). However, 3H-cholesterol fecal excretion (figure 2F) was increased by 29% in hamsters 161
Page 7 of 20 Diabetes
8
treated with empagliflozin (P<0.05). This data indicate that reduced intestinal cholesterol 162
absorption with empagliflozin treatment promotes fecal excretion of cholesterol deriving from 163
the macrophage. 164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
Page 8 of 20Diabetes
9
Discussion 181
The present study indicates that empagliflozin raises LDL-cholesterol levels only in fasting 182
conditions through reduction in LDL-cholesterol catabolism and alters cholesterol metabolism 183
at both the hepatic and intestinal levels in hamsters. 184
Overnight fasted hamsters treated with empagliflozin showed higher LDL-cholesterol levels 185
concomitant with higher free fatty acids and total ketone bodies plasma levels. The higher 186
level of total ketone bodies and fatty acids is in agreement with previous reports indicating 187
that chronic treatment with SGLT2 inhibitors induces ketogenesis and a metabolism switch 188
towards lipid oxidation to counter-balance the carbohydrate restriction in the fasting state (8-189
10). The excretion of glucose via urine and related calories loss with SGLT2 inhibition 190
therefore replicates starvation shift from carbohydrate to lipid utilization for energy in the 191
fasting state (11). Chronic SGLT2 inhibition also seems to mimic the LDL-raising effects of 192
ketogenic diet, in which LDL-cholesterol levels correlate with blood ketone bodies levels 193
(12). In the present study, evidence for a metabolic shift towards fat utilisation was also 194
observed at the liver level (e.g. hepatic glycogen and pyruvate levels) in fasted hamsters 195
treated with empagliflozin. The increased hepatic fatty acids levels, may fuel the pool of 196
acetyl-CoA, an important metabolic branch point, as a source for both ketone bodies 197
production and hepatic cholesterol synthesis (13), the later associated with a higher HMGCoA 198
reductase activity and hepatic total cholesterol levels. As hepatic levels of cholesterol 199
regulates LDL-receptor expression (14, 15) empagliflozin treatment lowered LDL-receptor 200
expression and plasma LDL-cholesterol catabolism, which in turns increased LDL-cholesterol 201
plasma levels. Although a raise in LDL-cholesterol levels is seen as an increase in 202
cardiovascular events risk (16), it is probably not so prominent with empagliflozin. Indeed, 203
the Empa Reg Outcome study recently delivered a spectacular 38% reduction in 204
cardiovascular mortality and 35% reduction in hospitalisation with heart failure, with no 205
Page 9 of 20 Diabetes
10
change in event rate of nonfatal myocardial infarction and non-fatal stroke (17). Moreover, 206
our study revealed that even after chronic treatment with empagliflozin, the increase in LDL-207
C was only observed in overnight fasted condition. In the clinical setting, LDL-C levels are 208
routinely assessed from plasma collected in the fasted state. Therefore, clinical investigations 209
evaluating the effects of empagliflozin on LDL-C levels in fed conditions would be of 210
interest. In addition, our in vivo experiments also highlighted potential anti-atherogenic 211
mechanisms induced by empagliflozin, such as LDL- and macrophage-derived fecal 212
cholesterol excretion. Macrophage-to-feces reverse cholesterol transport is known to be 213
inversely correlated with atherosclerosis (18) and an enhanced excretion of LDL-derived 214
cholesterol in the feces theoretically prevents its accumulation in the arterial wall. Whether 215
these mechanisms, besides body weight loss and blood pressure lowering, contribute to the 216
reduced cardiovascular risk in patients treated with empagliflozin (17) remains to be further 217
investigated. 218
Another point of investigation is the reduced intestinal cholesterol absorption observed in 219
hamsters treated with empagliflozin. Since a balance exists between hepatic cholesterol 220
synthesis and intestinal cholesterol absorption (19), the lower intestinal cholesterol absorption 221
may therefore result from the stimulation of hepatic cholesterol synthesis by empagliflozin. 222
However, the molecular mechanism by which empagliflozin alters intestinal cholesterol 223
metabolism remains to be elucidated. 224
In conclusion, the present study suggests that empagliflozin raises LDL-cholesterol levels 225
only in fasting condition by reducing LDL-receptor expression and LDL-cholesterol 226
catabolism. As illustrated in figure 3, the proposed mechanism leading to the LDL-C increase 227
originates from the metabolic switch toward lipid utilization, which triggers in parallel a 228
moderate activation of ketogenesis pathway and hepatic cholesterol synthesis within the liver. 229
Page 10 of 20Diabetes
11
Future studies to test whether SGLT2 inhibitors have similar rhythmic effect in plasma from 230
patients, fasted versus fed would be required. 231
232
Authors’ contribution: F.B., E.M, M.M. and T.S. designed research. F.B., E.B., N.B., I.U. 233
and C.C. conducted research, F.B. and E.M. analyzed data and wrote the paper. T.S. had 234
primary responsibility for final content. All authors have read and approved the final 235
manuscript. 236
237
Acknowledgements 238
The authors thank Dominique Lopes for animal care, Marjolaine Quinsat and Hélène Lakehal 239
for technical assistance; and Aurélie Couderc for quality control. 240
Guarantor: Thierry Sulpice is the guarantor of this work and, as such, had full access to all 241
the data in the study and takes responsibility for the integrity of the data and the accuracy of 242
the data analysis. 243
Conflict of interest: Eric Mayoux and Michael Mark are employees of Boehringer Ingelheim. 244
All other authors are employees of Physiogenex 245
246
247
248
249
250
Page 11 of 20 Diabetes
12
References 251
1 Nauck MA. Update on developments with SGLT2 inhibitors in the management of 252
type 2 diabetes. Drug Des Devel Ther 2014;8:1335-1380 253
2 Vivian EM. Sodium-glucose co-transporter (SGLT2) inhibitors: a growing class of 254
antidiabetic agents. Drugs Context 2014;3:212264 255
3 Maliha G, Townsend RR. SGLT2 inhibitors: Their potential reduction in blood 256
pressure. J Am Soc Hypertens 2015;9:48-53 257
4 Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle 258
HJ, Broedl UC, Kaspers S. Empagliflozin as adjunct to insulin in patients with type 1 259
diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 260
2015;17:928-935 261
5 Lund SS, Sattar N, Salsali A, Crowe S, Broedl UC, Ginsberg HN. Potential relevance 262
of changes in haematocrit to changes in lipid parameters with empagliflozin in patients with 263
type 2 diabetes (Abstract – P750). Diabetologia 2015;58(suppl 1):S360 264
6 Briand F, Thieblemont Q, Muzotte E, Sulpice T. Upregulating Reverse Cholesterol 265
Transport With Cholesteryl Ester Transfer Protein Inhibition Requires Combination With the 266
LDL-Lowering Drug Berberine in Dyslipidemic Hamsters. Arterioscler Thromb Vasc Biol 267
2013;33:01-11 268
7 Briand F, Thieblemont Q, Muzotte E, Sulpice T. High-fat and fructose intake induces 269
insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces 270
reverse cholesterol transport in hamsters. J Nutr 2012;142:704-709 271
8 Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidos. J 272
Clin Endocrinol Metab 2015;100:2849-528 273
274
Page 12 of 20Diabetes
13
9 Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi 275
S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y. 276
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid 277
oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74 278
10 Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle 279
HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic 280
patients. J Clin Invest 2014;124, 499-508 281
11 Aoki TT. Metabolic adaptations to starvation, semistarvation, and carbohydrate 282
restriction. Prog Clin Biol Res 1981;67:161-177 283
12 Johnston CS, Tjonn SL, Swan PD, White A, Hutchins H, Sears B. Ketogenic low-284
carbohydrate diets have no metabolic advantage over nonketogenic low-carbohydrate diets. 285
Am J Clin Nutr 2006;83:1055-1061 286
13 Coffee CJ. Branch point in Metabolism, p163. Book: Metabolism, Hayes Barton Press, 287
2004. ISBN-13: 978-1593771928 288
14 Brown MS, Golstein JL. A proteolytic pathway that controls the cholesterol content of 289
membranes, cells, and blood. Proc Natl Acad Sci 1999;96:11041-11048 290
15 Singh AB, Kan CF, Shende V, Dong B, Liu J. A novel posttranscriptional mechanism 291
for dietary cholesterol-mediated suppression of liver LDL receptor expression. J Lipid Res 292
2014;55:1397-1407 293
16 Ferrières J. Effects on coronary atherosclerosis by targeting low-density lipoprotein 294
cholesterol with statins. Am J Cardiovasc Drugs 2009;9:109-115 295
17 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, 296
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME 297
Page 13 of 20 Diabetes
14
Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. 298
New Engl J Med 2015;373:2117-2128 299
18 Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse 300
cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 301
2009;50:S189-S194 302
19 Miettinen TA, Gylling H, Viikari J, Lehtimäki T, Raitakari OT. Synthesis and 303
absorption of cholesterol in Finnish boys by serum non-cholesterol sterols: the cardiovascular 304
risk in Young Finns Study. Atherosclerosis 2008;200:177-183 305
Page 14 of 20Diabetes
15
Figures legends 306
307
Figure 1. Lipoprotein total cholesterol profiles assessed by Fast Protein Liquid 308
Chromatography from pooled plasma samples (A), representative western blots and 309
hepatic LDL-receptor protein expression after densitometry analysis (B), in vivo 310
intestinal 14C-cholesterol absorption (C) and fecal cholesterol mass excretion (D) in 311
hamsters treated with vehicle (white bars or open circles) or empagliflozin 30mg/kg/day 312
(black dashed bars or closed circles). *P<0.05, †P<0.01 and ‡P<0.001 vs. vehicle, n=9-10 313
hamsters/group. 314
315
Figure 2. 3H-cholesteryl oleate labeled LDL plasma decay curve over 72 hours and LDL-316
cholesteryl esters fractional catabolic rate (A), 3H-tracer recoveries in whole liver 317
homogenate, cholesterol and bile acids fractions (B), 3H-tracer recoveries in fecal 318
cholesterol and bile acids fractions (C) at time 72 hours after 3H-cholesteryl oleate 319
labeled LDL intravenous injection. 3H-tracer appearance in plasma over 72 hours (D), 320
3H-tracer recoveries in whole liver homogenate, cholesterol and bile acids fractions (E), 321
3H-tracer recoveries in fecal cholesterol and bile acids fractions (F) at time 72 hours 322
after 3H-cholesterol labeled/oxidized LDL loaded macrophages intraperitoneal injection. 323
Hamsters treated with vehicle or empagliflozin 30mg/kg/day are represented with white 324
bars, open circles or black dashed bars, closed circles). *P<0.05, †P<0.01 and ‡P<0.001 325
vs. vehicle, n=9-10 hamsters/group. 326
327
Page 15 of 20 Diabetes
16
Figure 3. Proposed mechanisms for the alteration of cholesterol metabolism by 328
empagliflozin. SGLT2 inhibition switches from carbohydrate to fat oxidation and 329
stimulates ketone bodies production and hepatic cholesterol synthesis in fasting 330
conditions. These metabolic alterations result in lower LDL-receptor expression and 331
moderate increase in LDL-cholesterol levels. The reduced intestinal cholesterol 332
absorption, which leads to higher macrophage- and LDL-derived cholesterol fecal 333
excretion remain to be further investigated. HMGCS1 & HMGCS2: 3-Hydroxy-3-334
Methylglutaryl-CoA synthases; HMGCoA red: 3-Hydroxy-3-methylglutaryl-CoA 335
reductase. 336
337
338
339
340
Page 16 of 20Diabetes
17
TABLE 1. Body weight and biochemical parameters in fed or overnight fast conditions. Data are mean ± SEM. *P<0.05 vs. vehicle;
†P<0.01 vs. vehicle; ‡P<0.001 vs. vehicle, n=9-10 hamsters/group.
fed conditions overnight fasting conditions
parameters vehicle empagliflozin 30mg/kg vehicle empagliflozin 30mg/kg
body weight (g) 110 ± 2 114 ± 2 110 ± 2 111 ± 1
hematocrit (%) 49.8 ± 0.7 47.9 ± 0.6* 48.3 ± 0.5 49.4 ± 0.6
plasma total protein (g/L) 81.2 ± 1.8 81.9 ± 1.8 79.6 ± 2.5 76.0 ± 1.0
blood glucose (mg/dL) 86.0 ± 5.5 88.6 ± 2.6 73.4 ± 4.0 59.9 ± 2.5*
Plasma total cholesterol (g/L) 4.0 ± 0.2 4.0 ± 0.2 3.0 ± 0.1 2.9 ± 0.2
Plasma LDL-cholesterol (g/L) 1.8 ± 0.1 1.6 ± 0.1 1.2 ± 0.1 1.5 ± 0.1*
Plasma ketone bodies (µM) 773 ± 76 909 ± 124 3094 ± 171 6685 ± 510‡
Plasma free fatty acids (mM) 0.62 ± 0.06 0.70 ± 0.05 0.45 ± 0.03 0.67 ± 0.05†
Plasma free glycerol (g/L) 0.023 ± 76 0.033 ± 0.004* 0.009 ± 0.001 0.011 ± 0.001
Liver weight (g) 5.61 ± 0.13 6.04 ± 0.13* 4.90 ± 0.13 4.75 ± 0.06
Hepatic triglycerides (mg/g liver) 15.1 ± 0.9 16.9 ± 0.1 16.6 ± 1.3 15.3 ± 0.7
Hepatic cholesterol (mg/g liver) 38.9 ± 0.8 40.2 ± 1.7 43.1 ± 1.9 47.7 ± 1.1*
Hepatic fatty acids (µmol/g liver) 362 ± 9 352 ± 12 386 ± 11 418 ± 8*
Hepatic ketone bodies
(µmol/g liver) 12.4 ± 0.5 12.1 ± 0.5
14.7 ± 0.6 16.8 ± 0.8
Hepatic pyruvate (µmol/g liver) 6.2 ± 0.5 6.4 ± 0.3 6.7 ± 0.4 8.0 ± 0.3*
Hepatic HMGCoAred activity
(mU/mg protein) 0.302 ± 0.034 0.357 ± 0.040
0.255 ± 0.019 0.334 ± 0.028*
Hepatic glycogen (mg/g liver) 39.1 ± 3.9 37.3 ± 2.2 4.31 ± 0.64 0.7 ± 0.4‡
Page 17 of 20 Diabetes
Figure 1.
Page 18 of 20Diabetes
Figure 2.
Page 19 of 20 Diabetes
Figure 3.
Page 20 of 20Diabetes